SuperworthREGENXBIO EV/EBIT RGNX
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 5.8×
- Feb 2023
- 8-year median
- 12.4×
- 8-year range
- 4.2× to 46.9×
- Peer median
- 9.2×
REGENXBIO has no meaningful EV/EBIT today: it made an operating loss of $164.1M over the last twelve months.
It was last meaningful in Feb 2023, at 5.8×.
On the days it had one over the last 8 years, its median was 12.4×, from 4.2× in May 2022 to 46.9× in Jul 2018.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2023 | 5.8× | 5.8× | 7.1× |
| 2022 | 6.3× | 4.2× | 9.8× |
| 2021 | n/m a value too high to mean anything | ||
| 2020 | n/m a value too high to mean anything | ||
| 2019 | 17.8× | 17.0× | 20.9× |
| 2018 | 16.2× | 15.0× | 46.9× |
Against its peers
Companies in Biotechnology nearest REGENXBIO's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| RGNXREGENXBIO | n/m |
| MGTXMeiraGTx | 4.6× |
| PLXProtalix BioTherapeutics | 7.5× |
| VCELVericel | 116× |
| ADMAAdma Biologics | 10.9× |
| Peer median | 9.2× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on REGENXBIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.